Galderma Group AG (XSWX:GALD) Stock Based Compensation: CHF52 Mil (TTM As of Dec. 2025)


XSWX:GALD Galderma Group AG XSWX:GALD
15 GF Score
Price CHF179.55
! 4 Warning Signs
View Full Analysis

What is Galderma Group AG Stock Based Compensation?

Galderma Group AG XSWX:GALD -0.42% 15 Stock Based Compensation is CHF52 Mil as of Dec. 2025. GuruFocus rates XSWX:GALD with a GF Score™ of 15/100. The stock has 4 warning signs investors should review.

Galderma Group AG's Stock Based Compensation for the six months ended in Dec. 2025 was CHF23 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was CHF52 Mil.

Galderma Group AG Stock Based Compensation Related Terms

Galderma Group AG Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Galderma Group AG's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galderma Group AG Stock Based Compensation Chart

Galderma Group AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
0.00 0.00 0.00 60.63 51.00

Galderma Group AG Semi-Annual Data
Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial 0.00 41.12 19.62 28.46 23.11
XSWX:GALD
15GF Score
Galderma Group AG XSWX:GALD
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galderma Group AG Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF52 Mil.

What does a Stock Based Compensation of CHF52 Mil mean?
Galderma Group AG (XSWX:GALD) has a Stock Based Compensation of CHF52 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Galderma Group AG and its competitors.
Is Galderma Group AG's Stock Based Compensation too high?
Galderma Group AG's current Stock Based Compensation is CHF52 Mil. Overall, Galderma Group AG has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's Stock Based Compensation compare to ZTS and UTHR?
Galderma Group AG's Stock Based Compensation of CHF52 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Galderma Group AG and its competitors. Galderma Group AG's current Stock Based Compensation is CHF52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current Stock Based Compensation of CHF52 Mil. The current Stock Based Compensation is CHF52 Mil. Galderma Group AG's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current Stock Based Compensation is CHF52 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galderma Group AG Business Description

Address Zahlerweg 10, Zug, CHE, 6300
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
15GF Score

Get the complete analysis for XSWX:GALD

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF179.55
Price